Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
77 studies found for:    "Autosomal dominant polycystic kidney disease"
Show Display Options
Download search resultsDownload the search results for:
"Autosomal dominant polycystic kidney disease" (77 records)
Download Content:
zip file readers with free trial periods: WinZip and PKZip
Rank Status Study
1 Enrolling by invitation Open-label Trial to Evaluate the Long Term Safety of Titrated Immediate-release Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease
Condition: Autosomal Dominant Polycystic Kidney Disease
Intervention: Drug: Tolvaptan (OPC-41061)
2 Withdrawn Repository Study of Autosomal Dominant Polycystic Kidney Disease
Condition: Autosomal Dominant Polycystic Kidney Disease
Intervention:
3 Completed
Has Results
Efficacy, Safety and Tolerability of Everolimus in Preventing End-stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney Disease
Condition: Autosomal Dominant Polycystic Kidney Disease
Interventions: Drug: Placebo;   Drug: Everolimus
4 Completed Adrenal Functions in Autosomal Dominant Polycystic Kidney Disease
Condition: Autosomal Dominant Polycystic Kidney Disease
Intervention: Drug: Tetracosactin
5 Completed 8-Week Study of Tolvaptan Dose Forms in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Condition: Autosomal Dominant Polycystic Kidney Disease
Interventions: Drug: Tolvaptan MR;   Drug: Tolvaptan IR;   Drug: Placebo
6 Terminated Sirolimus In Autosomal Dominant Polycystic Kidney Disease And Severe Renal Insufficiency
Condition: Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Interventions: Drug: Sirolimus;   Drug: conventional therapy
7 Completed Water as Therapy in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Condition: Autosomal Dominant Polycystic Kidney Disease
Intervention: Other: Water prescription
8 Completed Sirolimus (Rapamune®) for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Condition: Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Interventions: Drug: Sirolimus;   Other: Standard
9 Completed A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Study 156-04-001]
Condition: Autosomal Dominant Polycystic Kidney Disease
Intervention: Drug: OPC-41061
10 Completed A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) (2) [Extension of Study 156-05-002]
Condition: Autosomal Dominant Polycystic Kidney Disease
Intervention: Drug: OPC-41061
11 Not yet recruiting The Safety and Efficacy of Catheter-based Renal Denervation Using the Vessix™ Renal Denervation System in Autosomal Dominant Polycystic Kidney Disease (ADPKD) Patients With Severe Debilitating Pain
Condition: Autosomal Dominant Polycystic Kidney Disease
Intervention: Device: Vessix
12 Active, not recruiting Somatostatin In Patients With Autosomal Dominant Polycystic Kidney Disease And Moderate To Severe Renal Insufficiency
Condition: Autosomal Dominant Polycystic Kidney Disease.
Interventions: Drug: Octreotide-LAR;   Other: Saline solution.
13 Recruiting Safety, Pharmacokinetics, Tolerability and Efficacy of Tolvaptan in Children and Adolescents With ADPKD (Autosomal Dominant Polycystic Kidney Disease)
Condition: Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Interventions: Drug: Tolvaptan;   Drug: Matching Placebo
14 Unknown  Triptolide-Containing Formulation as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Condition: Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Interventions: Drug: Triptolide-Containing Formulation;   Drug: Placebo
15 Completed Observational Study in Patients With Autosomal Dominant Polycystic Kidney Disease
Condition: Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Intervention:
16 Completed A Study to Investigate the Long-term Safety and Efficacy of Tolvaptan in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Trial 156-04-251 in Japan]
Condition: Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Intervention: Drug: tolvaptan
17 Active, not recruiting Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease
Conditions: Chronic Kidney Disease;   Autosomal Dominant Polycystic Kidney Disease
Interventions: Drug: Tolvaptan (OPC-41061);   Drug: Placebo
18 Completed New Quantitive MRI Parameters in Assessing Kidneys of Autosomal Dominant Polycystic Kidney Disease
Conditions: Autosomal Dominant Polycystic Kidney Disease;   Kidney Disease
Intervention:
19 Terminated
Has Results
Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD): The Role of Biomarkers in Predicting a Response to Therapy
Condition: Autosomal Dominant Polycystic Kidney Disease
Interventions: Drug: Rapamycin;   Other: Standard of Care-Placebo
20 Active, not recruiting Clinical Implications of DNA Analysis on ADPKD
Condition: Autosomal Dominant Polycystic Kidney Disease
Intervention:

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.